Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Futura Medical ( (GB:FUM) ) is now available.
Futura Medical reported positive results from a four-week home user test comparing its marketed erectile dysfunction gel Eroxon with prototype formulation Eroxon Intense in 223 U.K. men, mostly with mild to moderate erectile dysfunction. Both products showed high efficacy, with strong improvements in erectile function versus baseline and high satisfaction with erection hardness and duration, especially when applied by a partner.
The study confirmed that Eroxon Intense delivers a statistically stronger sensorial effect than the current formulation in the first two minutes after application, while both gels were well tolerated by men and their partners. Futura plans to target consumers under 60 with mild to moderate erectile dysfunction and to promote partner use as part of foreplay, and has already filed a Special 510(k) submission with the U.S. FDA and generated data to support regulatory filings in Europe for Eroxon Intense, with regulatory decisions expected in the first half of 2026.
The most recent analyst rating on (GB:FUM) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
Spark’s Take on FUM Stock
According to Spark, TipRanks’ AI Analyst, FUM is a Neutral.
The score is held back most by the earnings call’s sharply reduced FY2025 outlook and short cash runway, plus weak technical trend signals. These risks are partially offset by the FY2024 profitability turnaround and a zero-debt balance sheet, though negative free cash flow keeps financial quality mixed.
To see Spark’s full report on FUM stock, click here.
More about Futura Medical
Futura Medical is a U.K.-listed consumer healthcare company specialising in the research, development and global commercialisation of topically delivered gel formulations for sexual health. Its lead product, Eroxon, is the only over-the-counter topical gel treatment for erectile dysfunction, complemented by development candidates including Eroxon Intense and WSD4000 for female sexual dysfunction.
Average Trading Volume: 6,592,188
Technical Sentiment Signal: Sell
Current Market Cap: £6.7M
Find detailed analytics on FUM stock on TipRanks’ Stock Analysis page.